Clinical trial for the safety and efficacy of CS1-targeted CAR-T Cells therapy for relapsed multiple myeloma after BCMA CAR-T cells therapy
Histologically confirmed diagnosis of CS1+ multiple myeloma (MM)：
Patients with MM relapsed after BCMA CAR-T therapy;Or MM with positive CS1 expression and negative BCMA expression;
Relapsed after hematopoietic stem cell transplantation;
Cases with recurrent positive minimal residual disease;
History of craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular hemorrhagicdiseases;
Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past;
Pregnant (or lactating) women;
Patients with severe active infections (excluding simple urinary tract infectionand bacterial pharyngitis);
Zhejiang University
Lead sponsor
Yake Biotechnology Ltd.
Collaborator